

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants with Fragile X Syndrome

Status: Recruiting

Eligibility Criteria

Sex: Male

Age Group: Not specified

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- male, ages 13-45 - diagnosed with Fragile X syndrome (FXS) confirmed through genetic testing - able to complete study activities that assess language and thinking abilities - have a consistent caregiver who is willing and able to provide regular support during the study - able to swallow tablets or capsules - see link to clinicaltrials.gov for complete inclusion criteria

Conditions & Interventions

Interventions:

Drug: High dose of MRM-3379, Drug: Low dose of MRM-3379, Drug: Low dose of MRM-3379 Open-Label, Drug: Middle Dose of MRM-3379, Drug: Placebo

Conditions:

Rare Diseases, Brain & Nervous System

Keywords:

Fragile X Syndrome, FXS

More Information

Description: Researchers are studying an investigational medication called MRM-3379 for males with Fragile X syndrome (FXS), a genetic condition that can affect learning, memory, communication, and behavior. The goal of this study is to evaluate the safety and tolerability of MRM-3379 and explore whether it may help improve cognitive function by supporting brain cell communication. The study will also examine how the body processes the medication.

Study Contact: Rachel Floersch - floer013@umn.edu

Principal Investigator: Amy Esler

Phase: PHASE2

IRB Number: STUDY00027846

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.